FDA approved short-term acute pain prodrugs

Source: Wuxi Pharmaceutical Co., Ltd., February 26, 2018 kempharm, recently announced that the US FDA approved its apadaz Gamma New drug application (NDA) Apadaz Gamma It is suitable for the treatment of short-term (no more than 14 days) acute severe pain (opioid analgesics are required and there is no appropriate alternative therapy) Apadaz is a combination of benzhydrocodone and acetaminophen (APAP), the precursor of kempharm Apadaz is the first FDA approved precursor of hydrocodone / acetaminophen Kempharm believes that apadaz is unique in prescription opioids because it contains a chemically inert or inactive prodrug When ingested, enzymes in the gastrointestinal tract cleave ligands and release the parent drug (hydrocodone) to play its therapeutic effect Kempharm is a pharmaceutical company focused on the discovery and development of patented precursor drugs, using ligand activation therapy (LAT (E) Platform technology creates new molecular entity (NME) precursor drugs to improve one or more properties of approved drugs, such as abuse, bioavailability, and safety Kempharm has used its lat Gamma The prodrug platform has developed a series of prodrugs for the treatment of pain, attention deficit hyperactivity disorder (ADHD) and other central nervous system indications ▲ product pipeline overview of kempharm (photo source: Official Website of kempharm), said Dr Travis mickle, President and CEO of kempharm: "the approval of apadaz is an important milestone for kempharm, which creates a business opportunity for our differentiated products for the treatment of short-term acute pain Based on the unique properties of this drug, we believe that apadaz will have market opportunities We are very happy that apadaz can provide new treatment methods for patients and doctors who can choose prescription differentiation products " "This approval is a groundbreaking lat for kempharm Gamma "Kempharm is first and foremost a company that develops precursor drugs," said Dr mickle Apadaz's approval shows lat Gamma There is a huge potential in the discovery and development of patented precursors designed to be widely prescribed, differentiated versions of approved drugs, and to successfully complete rigorous regulatory processes " We congratulate on the approval of the new drug, and look forward to the new drug for more patients with short-term acute pain.